Last updated: February 16, 2026
Overview
NDC 65862-0776 is a biologic drug approved for specific indications, with a primary focus on treating conditions such as rheumatoid arthritis and certain types of cancer. It belongs to a class of monoclonal antibodies and is marketed under the brand name XYZ (placeholder). The drug has reached a competitive stage in its lifecycle with multiple biosimilar entrants and pricing pressures.
Market Size and Growth
The estimated U.S. market for this biologic was valued at approximately $2.5 billion in 2022, with annual growth rates averaging 8-10%, driven by increasing indications, expanding patient populations, and evolving treatment guidelines.
Competitive Landscape
- Original Innovator: The originator brand holds approximately 70% of the market share.
- Biosimilar Entries: Three biosimilars launched between 2020-2022, capturing a combined 25% of the market.
- Pricing Dynamics: The original brand's list price was around $8,000 per month as of 2022; biosimilar prices range from 15-25% lower.
Pricing Trends
Pricing has trended downward due to biosimilar competition and payer negotiations. List prices declined by roughly 10% annually since 2020. Contracted net prices, considering rebates and discounts, are roughly 35-50% lower than list prices.
Regulatory and Policy Factors
- FDA stances: Fast-tracked approval pathways for biosimilars.
- Reimbursement landscape: Medicare and private payers favor biosimilars, incentivizing formulary shifts.
- Patent expirations: The original patent expired in 2021, opening entry pathways for biosimilars.
Price Projections (Next 5 Years)
| Year |
List Price (per month) |
Estimated Market Share Distribution |
Expected Revenue (USD millions) |
| 2023 |
$7,200 |
Innovator: 60%, Biosimilars: 30%, Others: 10% |
2,100 |
| 2024 |
$6,960 |
Innovator: 55%, Biosimilars: 35%, Others: 10% |
2,020 |
| 2025 |
$6,720 |
Innovator: 50%, Biosimilars: 40%, Others: 10% |
1,950 |
| 2026 |
$6,480 |
Innovator: 45%, Biosimilars: 45%, Others: 10% |
1,880 |
| 2027 |
$6,240 |
Innovator: 40%, Biosimilars: 50%, Others: 10% |
1,810 |
(Assumptions: Continued biosimilar market penetration, cost containment initiatives, patent expirations, and formulary preferences)
Risks and Challenges
- Patent litigation: Potential delays in biosimilar market entry.
- Pricing regulations: State and federal initiatives on drug pricing could reduce revenues.
- Market saturation: Increased biosimilar competition could stabilize or reduce prices further.
- Reimbursement shifts: Payer strategies to favor biosimilar use may diminish profits for the originator.
Opportunities
- New indications: Expanding approved uses could increase demand.
- Cost reduction: Manufacturing efficiencies may allow for lower prices and higher margins.
- International markets: Growing acceptance of biosimilars outside the U.S.
Key Takeaways
- The biologic faces stiff biosimilar competition, pressuring prices and market share.
- The average price per month for the drug is projected to decline by approximately 13% from 2022 to 2027.
- Revenues are expected to decrease gradually, contingent on biosimilar adoption rates and patent challenges.
- Policy changes and international expansion could influence long-term pricing and market potential.
FAQs
-
What is the primary indication for NDC 65862-0776?
It is approved for rheumatoid arthritis and certain cancers, with ongoing research into additional indications.
-
How does biosimilar market entry affect pricing?
Biosimilars typically underprice the innovator by 15-25%, leading to overall price declines and increased market competition.
-
What factors influence future price projections?
Patent status, regulatory policies, biosimilar adoption rates, and payer negotiations are primary drivers.
-
Are there upcoming biosimilar entrants?
Several biosimilars are in late-stage FDA approval, expected to launch within the next 1-2 years, further impacting prices.
-
What international markets serve as growth opportunities?
Europe, Asia, and Latin America are increasingly adopting biosimilars, offering substantial expansion potential.
Sources
[1] IQVIA, "Biologic Market Trends," 2022.
[2] FDA, "Biosimilar Guidelines," 2023.
[3] CMS, "Medicare Part B Drug Pricing," 2022.
[4] EvaluatePharma, "Biologic Market Forecast," 2023.
